We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
-9.33%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$661M
AUM Growth
-$84.6M
Cap. Flow
-$6.68M
Cap. Flow %
-1.01%
Top 10 Hldgs %
76.63%
Holding
30
New
8
Increased
5
Reduced
6
Closed
8

Top Buys

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$49M
2
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$48.7M
3
NUVA
NuVasive, Inc.
NUVA
+$45.6M
4
ASRT
Assertio
ASRT
+$42.6M
5
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$39M

Top Sells

Rank Stock Value
1
INSY
Insys Therapeutics, Inc.
INSY
+$73.5M
2
AKRX
Akorn Inc
AKRX
+$70.7M
3
LCI
Lannett Company, Inc.
LCI
+$52.8M
4
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$45.2M
5
OSIR
Osiris Therapeutics, Inc. Common Stock
OSIR
+$23.3M

Sector Composition

Rank Sector Weight
1 Healthcare 90.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRX
26
DELISTED
Akorn Inc
AKRX
– –
-1,893,756
Closed -$70.7M
INSY
27
DELISTED
Insys Therapeutics, Inc.
INSY
– –
-2,568,684
Closed -$73.5M
MSLI
28
DELISTED
Merus Labs International Inc.
MSLI
– –
-28,484
Closed -$47K
CTIC
29
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-51,000
Closed -$635K
OSIR
30
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
– –
-2,240,709
Closed -$23.3M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, Consonance Capital Management held 30 positions worth $661M, down 11% from $745M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Consonance Capital Management's Q1 2016 filing shows 8 new, 5 increased, 6 reduced and 8 closed positions. Its largest new stake was MEDIVATION, INC.: 1,350,000 shares worth $62.1M. The largest sale was Insys Therapeutics, Inc., an estimated $73.5M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 90% a quarter earlier.

  • Consonance Capital Management's largest Q1 2016 buy was MEDIVATION, INC.: 1,350,000 shares worth $62.1M.
  • Consonance Capital Management added most to MALLINCKRODT PUBLIC LIMITED COMPANY in Q1 2016, an estimated $22.4M increase.
  • Consonance Capital Management's biggest Q1 2016 reduction was Eagle Pharmaceuticals, Inc., cutting an estimated $45.2M.
  • Consonance Capital Management fully exited Insys Therapeutics, Inc. in Q1 2016, selling an estimated $73.5M.
  • Consonance Capital Management's ten largest holdings make up 77% of its $661M portfolio in Q1 2016.
  • Consonance Capital Management opened 8 new positions and closed 8 in Q1 2016.
  • Consonance Capital Management's portfolio value fell 11% quarter-over-quarter to $661M.

Based on Consonance Capital Management's 13F filing for Q1 2016, filed 16 May 2016.